Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

ClinRx Research LLC

Neither a doctor nor a teaching hospital

Research payments

$5,600,337

520 payments

Through program year 2025, ClinRx Research LLC is reported as receiving $5,600,337 in research payments, across 520 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $614,205 64
2024 Research $645,168 54
2023 Research $870,805 68
2022 Research $1,547,589 93
2021 Research $857,177 103
2020 Research $873,434 114
2019 Research $191,959 24

Breakdown

Who paid Research payments · program years 2019–2025
  1. Vanda Pharmaceuticals Inc. $3,785,466 150 payments
  2. AbbVie, Inc. $744,632 198 payments
  3. Astellas Pharma Global Development $511,751 45 payments
  4. Allergan Inc. $134,045 48 payments
  5. GlaxoSmithKline, LLC. $117,086 52 payments
  6. Hikma Pharmaceuticals USA $101,457 4 payments
  7. American Regent $89,966 1 payment
  8. Pfizer Inc. $87,983 9 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $27,953 13 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy of Tradipitant in Relieving Symptoms of Gastroparesis $2,341,231 63 payments
  2. Evaluating the Safety and Efficacy of Tradipitant VS. Placebo in Idiopathic and Diabetic Gastroparesis $1,399,640 67 payments
  3. A Phase IV, Longitudinal, Observational Study Examining Real-World Outcomes of Non-Hormonal Pharmacotherapies Among Individuals Treated for Bothersome Vasomotor Symptoms $511,751 45 payments
  4. Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $176,592 37 payments
  5. M16-100 $150,209 19 payments
  6. M16-283 $135,428 32 payments
  7. A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men $112,174 27 payments
  8. Tpx-100 $89,966 1 payment
  9. A Phase 3 Randomized Doubleblind Activecontrolled Multicenter Study of the Longterm Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip Or Knee $86,122 8 payments
  10. AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis $63,091 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record